Among cancer gene deletions, CDKN2A loss defined multiple subgroups associated with poor survival including papillary kidney cancer (c1), low-grade glioma (c4), lung adenocarcinoma (c4), and soft tissue sarcoma (c1) (Additional file 1: Fig. S6 and S7). Here, CDKN2A is linked to glioma.